Framework for implementing treat-to-target in systemic lupus erythematosus routine clinical care: consensus

Matteo Piga1, Ioannis Parodis2, Zahi Touma3

  • 1Rheumatology Unit, Department of Medical Sciences and Public Health, AOU Cagliari and University of Cagliari, Italy.

Autoimmunity Reviews
|February 17, 2025
PubMed

Insights

Implementing Treat-to-Target (T2T) for systemic lupus erythematosus (SLE) is challenging. This framework offers practical guidance for physicians to improve SLE patient care using T2T strategies, addressing current clinical practice gaps.

Area of Science:

  • Rheumatology
  • Clinical Practice Guidelines
  • Systemic Lupus Erythematosus Research

Background:

  • Treat-to-Target (T2T) implementation in systemic lupus erythematosus (SLE) clinical practice is notably low.
  • Real-world evidence indicates excessive glucocorticoid (GC) use and suboptimal disease control in SLE patients.
  • Existing T2T recommendations for SLE lack a practical framework for routine clinical application.

Purpose of the Study:

  • To develop a consensus framework for implementing Treat-to-Target (T2T) in the routine clinical care of adult patients with SLE.
  • To provide actionable strategies for physicians to enhance SLE management through T2T principles.
  • To address challenges and propose future research directions for T2T in SLE.

Main Methods:

  • An international task force of 22 SLE physicians and 3 lupus patient research partners was convened.
  • A scoping review of T2T definitions and instruments for SLE was conducted, followed by online discussions.
  • A Delphi consensus process was used to develop and agree upon framework statements for T2T implementation in SLE.

Main Results:

  • The developed framework includes 5 overarching principles and 11 actionable statements for T2T implementation in SLE.
  • The framework aims to bridge the gap between T2T recommendations and real-world clinical practice.
  • Analysis identified current barriers to T2T adoption and areas for future research in SLE management.

Conclusions:

  • A consensus framework for implementing Treat-to-Target (T2T) in SLE has been established to guide clinical practice.
  • This framework provides a real-world perspective to improve SLE patient outcomes by optimizing disease management.
  • The initiative seeks to inform a broader range of healthcare providers, including non-specialists, about effective T2T strategies in SLE.

Related Concept Videos

Pulmonary Tuberculosis V01:28

Pulmonary Tuberculosis V

Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
168
Autoimmune Disorders01:29

Autoimmune Disorders

Autoimmune diseases are a group of disorders in which the body's immune system mistakenly attacks its own cells, tissues, and organs. This results from an overactive immune response against substances and tissues normally present in the body. Let's delve into the concept and mechanism of autoimmune diseases from an immune system point of view, explore different causes and examples of such diseases, and discuss potential solutions.
Concept and Mechanism of Autoimmune Diseases
The immune...
379
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.4K